Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04000607

Exploratory Study of the Edwards APTURE Transcatheter Shunt System (ALT-FLOW Canada)

The Exploratory study of the Edwards APTURE transcatheter shunt system (APTURE system) is a multi-center, prospective, exploratory study to evaluate initial clinical safety, device functionality, and effectiveness of the APTURE system.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Heart Failure Cardiovascular Diseases Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Symptomatic HF:
  • NYHA II w/ history of > II; III; or ambulatory IV AND
  • ≥1 HF hospitalization OR treatment with IV or oral diuresis within 12 months OR Elevated NT-proBNP value > 150 pg/ml in normal sinus rhythm, >450 pg/ml in atrial fibrillation, OR a BNP value > 50 pg/ml in normal sinus rhythm, > 150 pg/ml in atrial fibrillation within the past 6 months prior to study entry
  • On stable GDMT for HF
  • Left Ventricular Ejection Fraction (LVEF) ≤ 40% as determined by site cardiologist
  • Hemodynamic criteria

o At rest: Elevated LAP (or PCWP) > 15 mmHg AND LAP > RAP + 5 mmHg AND/OR supine ergometer exercise: elevated LAP (or PCWP) > 25 mmHg AND LAP > RAP + 10 mmHg

  • Pulmonary Vascular Resistance (PVR) < 5.0 WU as determined by site cardiologist

Exclusion criteria

  • Severe HF:
  • NYHA IV, stage D, non-ambulatory, transplant list
  • Cardiac index ≤ 1.5 L/min/m2
  • Left Ventricular End-Diastolic Diameter (LVEDD) > 8 cm
  • LVEF <20%
  • Valve disease
  • MR >3+ or > moderate MS, TR >3+ (severe on 5-point scale), AR >2+,
  • OR > moderate AS
  • MI or therapeutic invasive cardiac procedure < 3 months
  • TIA, stroke, CRT implanted < 6 months
  • RV dysfunction > mild by TTE OR TAPSE <1.2 OR RV size ≥ LV size by TTE, OR Right Ventricular Fractional Area Change (RVFAC) ≤ 25%
  • Dialysis OR renal dysfunction (S-Cr > 220 micromol/L OR e-GFR < 25ml/min/1.73 m2)
  • 6MWT <50m OR >400m
  • Active endocarditis or infection < 3 months
  • Mean Right Atrial Pressure (mRAP) > 15 mmHg as determined by site cardiologist
  • Body Mass Index (BMI) ≥ 45 kg/m2

Treatment and study plan

APTURE transcatheter shunt

Device

Transcatheter treatment of symptomatic left heart failure patients

Primary outcomes

  1. Rate of major cardiac/cerebrovascular/renal events and re-intervention (Safety Endpoint)

    Time frame: 30 Days

    Composite of major adverse cardiac, cerebrovascular, renal events (MACCRE) and re-intervention for study device related complications at 30 days.

Secondary outcomes

  1. Rate at which device is successfully implanted (Device Success)

    Time frame: Day 0

    Device is deployed as intended and the delivery system is successfully removed as intended at the time of the patient's exit from the implant procedure room.

  2. Rate at which device is patent and subject is discharged from hospital without the need for additional intervention for the device (Procedural Success)

    Time frame: 10 Days post-op

    Device success with evidence of shunt patency and hospital discharge without the need for additional surgical or percutaneous intervention related to the study device including unacceptable Qp/Qs values.

  3. Rate at which the procedure is successful without major cardiac/cerebrovascular/renal events and re-intervention (Clinical Success)

    Time frame: 30 Days

    Procedural success without major adverse cardiac, cerebrovascular, and renal events (MACCRE) and re-intervention for study device related complications at 30 days.

  4. Change in the ratio of systemic blood flow (Qs) to the pulmonary blood flow (Qp), called "Qp/Qs", from Baseline to Follow Up

    Time frame: 3 Months, 6 Months

    Change in Qp/Qs value from Baseline to Follow Up (3Month, 6Month)

  5. Change in pulmonary capillary wedge pressure (PCWP) from Baseline to Follow Up

    Time frame: 3 Months, 6 Months

    Change in PCWP value from Baseline to Follow Up (3Month, 6Month)

  6. Change in mean systolic & diastolic pulmonary artery pressure (PAP) and change in mean right atrial pressure (RAP) from Baseline to Follow Up

    Time frame: 3 Months, 6 Months

    Change in PAP and RAP values from Baseline to Follow Up (3Month, 6Month) under the same test conditions (e.g. comparison in the value at rest at baseline, to at rest at follow up; comparison in the value at exercise at baseline, to at exercise at follow up)

  7. Change in Pulmonary Vascular Resistance (PVR) from Baseline to Follow Up

    Time frame: 3 Months, 6 Months

    Change in PVR value from Baseline to Follow Up (3Month, 6Month) under the same test conditions (e.g. comparison in the value at rest at baseline, to at rest at follow up; comparison in the value at exercise at baseline, to at exercise at follow up)

  8. Change in two parameters related to Tricuspid Annular Plane Excursion (TAPSE) from Baseline to Follow Up

    Time frame: 3 Months, 6 Months

    Change in two parameters from Baseline to Follow Up (3Month, 6Month):

    • "TAPSE", Tricuspid Annular Plane Excursion
    • "TAPSE/sPAP", Tricuspid Annular Plane Excursion (TAPSE) divided by the systolic pulmonary Artery Pressure (sPAP)

Sponsors and collaborators

Lead sponsor

Edwards Lifesciences

Industry

Registry information

Important dates

Study start
2019
Primary completion
2023
Study completion
2028
First posted
Jun 27, 2019
Registry last updated
Jan 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.